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a b s t r a c t   
A method for the quantitative analysis of delta-9-tetrahydrocannabinol (THC, the main active ingredient of 
cannabis) in whole blood using solid phase extraction and LC/MS/MS has been developed. A bottom-up 
approach with method validation data was used to evaluate and estimate the measurement uncertainty 
(MU) of the analytical method. The sources of uncertainty were identified using a cause and effect diagram. 
The contribution of each uncertainty component was estimated and were combined to derive the overall 
uncertainty of the analytical method. The combined uncertainty was estimated to be 0.131 μg/L (< 7%). At a 
99.7% confidence level, the expanded uncertainty was 0.393 μg/L for a THC concentration of 2 μg/L in a 
whole blood sample. The calculations not only enable the laboratory to quantify the uncertainty associated 
with a quantitative result, but can also be used to identify the sources of uncertainty and determine if the 
analytical method can be improved. 
© 2021 The Authors. Published by Elsevier B.V. 
CC_BY_4.0   
1. Introduction 
It is becoming increasingly important and a necessity for forensic 
toxicologists to quantify and report the measurement uncertainty 
(MU) associated with their analytical methods [1,2]. For accredita-
tion standards such as ISO/IEC 17025 [3], it is now a fundamental 
requirement of quality management systems that many forensic 
toxicology laboratories adhere to, not only to identify the sources of 
uncertainty that may contribute to an analytical measurement, but 
also to estimate the size of their contribution. 
Every measurement or analytical result will have an associated 
uncertainty [4,5], partly due to inevitable errors from random ef-
fects. In a field where the interpretation of a quantitative drug result 
is commonplace, it is essential to know the MU associated with a 
quantified drug concentration to ensure its appropriate interpreta-
tion. This is particularly vital when comparing quantitative results to 
a legal limit, such as for drink-driving or drug-driving cases. The 
toxicologist must be confident that a drug level exceeds the legal 
limit before reporting the result for the purpose of the judicial 
system. In order to do this, they must evaluate and take into account 
the MU of their analytical result. 
Uncertainty as defined in the International Vocabulary of 
Metrology (VIM) [6] is a “non-negative parameter characterizing the 
dispersion of the quantity values being attributed to a measurand, 
based on the information used”. Appropriately quantifying this 
parameter will yield a range of values that is believed to contain 
the true unknown value of the measurand, thereby serving as a 
key indicator of measurement reliability and suitability for 
purpose [4,7,8]. 
The most common methods to estimating MU are either the 
bottom-up or top-down approach. The bottom-up approach requires 
a systematic evaluation and a clear description of all possible sources 
of uncertainty contributing to a measured quantity. To achieve this, a 
formula underlying the relationship between a measurand and its 
parameters must be clearly specified and all contributing un-
certainties quantified using statistical modelling techniques. The 
top-down approach uses existing data and information from la-
boratory test performance and does not require one to system-
atically identify the source of uncertainty in each step of quantifying 
a measurand. Existing data from laboratory proficiency test, intra- 
and inter-laboratory studies, method validation and quality control 
data can be used to estimate MU [9–11]. 
Studies comparing both approaches have found no significant 
difference between the MU values obtained from top-down and 
bottom-up approaches, thereby concluding that both approaches are 
approximately equivalent and opted for the use of top-down ap-
proaches as a simpler method [10,12]. 
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While the bottom-up approach can be very challenging and, in 
some cases, too complex to implement, it enables practitioners to 
optimise an analytical method as all possible uncertainty sources at 
each stage of the process are likely to be detected and included in 
the estimation process, as well as finding improvements [12,13]. 
In this paper, a specific method for the quantitative analysis of 
delta-9-tetrahydrocannabinol (THC, the main active ingredient of 
cannabis) in whole blood using solid phase extraction and LC/MS/MS 
is used to illustrate a possible way of evaluating and estimating the 
MU of a quantitative analytical method using a bottom-up approach. 
The sources of uncertainty are identified using a cause and effect 
diagram. Method validation data is used to outline a step-by-step 
approach to estimating their contribution to, and the overall un-
certainty of, the analytical method. 
The methodology underpinning the calculations in deriving the 
overall uncertainty is being used to develop an open access 
Measurement Uncertainty Calculator (MUCalc) software as part of a 
statistical tool box project developed by the Leverhulme Research 
Centre for Forensic Science (LRCFS) for forensic practitioners 
(see Appendix B). 
This study and the ongoing application development provide a 
more detailed methodical analysis of how each uncertainty com-
ponent can be calculated, providing full data sets for each compu-
tation in order to make it easy for practitioners needing to calculate 
MU to follow. 
2. Experimental 
2.1. Chemicals and reagents 
Certified reference standard solutions of Δ9-THC and Δ9-THC - d3 
(internal standard) were obtained from Cerilliant (Sigma-Aldrich, UK) 
at concentrations of 1.00 and 0.100 mg/mL in methanol respectively. 
An independent certified reference standard solution of Δ9-THC 
(1.00 mg/mL in methanol) was obtained from Chiron (Chiron UK Ltd, UK) 
for quality control purposes. All other chemicals and solvents were 
purchased from Fisher Scientific UK Ltd, UK, Rathburn Chemicals, UK 
and VWR International, UK. 
THC-free human whole blood (blank blood) was obtained from 
the Scottish National Blood Transfusion Service (SNBTS). 
2.2. Preparation of stock and working standard solutions 
For the calibration curve, THC stock solution ACAL was prepared 
by diluting 20 μL of the Cerilliant certified reference standard to 2 mL 
with methanol. This was subsequently diluted 200- and 100-fold to 
give working solutions BCAL (50 μg/L) and CCAL (100 μg/L), respec-
tively. 
THC-d3 stock solution AIS was prepared by diluting 12 μL of the 
Cerilliant certified reference standard to 1.2 mL with methanol. This 
was then diluted 20-fold to give working solution BIS (50 μg/L). 
For the quality control samples, THC working stock AQC was 
prepared by diluting 20 μL of the Chiron certified reference standard 
to 2 mL with methanol. This was then diluted 100-fold to give 
working solution BQC (100 μg/L). 
2.3. Calibration and quality control (QC) 
Working solutions BCAL and CCAL were used to prepare calibrators 
(1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0 and 10 μg/L) in blank whole 
blood and the calibration curve was constructed using a least-square 
linear regression. Linear regression analysis was performed on the 
peak area ratios of the analyte to internal standard versus the ana-
lyte concentrations. 
Quality control samples were prepared by spiking blank blood 
with the QC working solution BQC to give Low (2.0 μg/L), Medium 
(5.0 μg/L), and High (10.0 μg/L) QC samples. Three replicates for each 
of the three concentration levels were analysed over 11 different 
days using a freshly prepared calibration line each day. 
2.4. Sample preparation 
To 0.5 mL blood, 50 μL of methanol and 20 μL internal standard 
(THC-d3) were added. The sample was precipitated by adding cold 
acetonitrile (2 mL) and then vortex mixed and centrifuged. The 
sample was concentrated under a flow of nitrogen and 3 mL of 0.1 M 
acetate buffer (pH4) added. Sample extraction was performed using 
a United Chemical Technologies Inc. (UCT) CleanScreen® SPE column 
(200 mg/3 mL) (Chromatography Direct, UK) installed on an 
Extrahera™ automated system (Biotage AB, Sweden). The column 
was conditioned with methanol, water and 0.1 M acetate buffer 
(pH 4). The sample was then loaded onto the column and the column 
washed with water and 0.1 M hydrochloric acid:acetonitrile (80:20). 
The sample was eluted with hexane and hexane:ethyl acetate 
(65:35) and the extract dried and reconstituted in acetonitrile 
(50 μL) for LC/MS/MS analysis. 
2.5. Instrumentation 
The analysis was conducted using an Agilent 1260 Infinity II 
Prime LC System coupled with an Agilent Ultivo triple quadrupole 
LC/MS (VWR International, UK). Chromatographic separation of a 
10 μL injection was achieved at 50 °C and a flow rate of 0.5 mL/min 
using a ZORBAX RRHD Eclipse Plus C18 column (2.1 mm × 50 mm, 
1.8 μm, Crawford Scientific, UK) with a complementary guard 
column. Mobile phase A was 2 mM ammonium formate, 0.4 mM 
ammonium fluoride, 0.1% formic acid in water and mobile phase B 
was 2 mM ammonium formate, 0.4 mM ammonium fluoride, 0.1% 
formic acid in methanol. The gradient started with 70% mobile phase B, 
which was increased to 95% in 4 min and then held for 0.5 min. 
The column was re-equilibrated at 70% B for 0.1 min. The AJS ESI was 
operated in MRM mode. MRM transitions monitored for THC were 
m/z 315 → 193 with qualifiers 315 → 123 and 315 → 259; and for 
THC-d3 m/z 318 → 196 with qualifier 318 → 123. The LC/MS/MS 
system was controlled using MassHunter Data Acquisition Software 
and data analysis was performed using MassHunter Quantitative 
Analysis software (version B.09.00). 
2.6. Method validation 
The method was validated in line with international guidelines  
[14–17] establishing selectivity, matrix effects, limit of detection 
(LOD), lower limit of quantitation (LLOQ), linearity, precision, accu-
racy, carryover, stability and dilution integrity. QC samples were 
prepared, extracted and analysed in triplicate on 11 days alongside a 
freshly prepared calibration curve to determine accuracy and 
precision. These results were used to estimate the measurement 
uncertainty of the method. 
3. Identifying uncertainty sources 
3.1. Specifying the measurand 
The measurand is the concentration of the THC analyte (μg/L) in a 






where xcs is the amount of THC in the case sample, V is the volume of 
the case sample. 
Updating the measurement function with additional influencing 
factors from method precision [18,19], Eq. (1) becomes 
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= × µx x
V
f ( g L)THC
cs
precision (2) 
where fprecision is the correction factor for method precision. 
3.2. Sources of uncertainty 
With reference to Eq. (2), the sources of uncertainties associated 
with quantifying THC in blood are identified using the cause and 
effect diagram displayed in Fig. 1. The main uncertainty sources 
are from method precision, sample volume (in estimating V), cali-
bration curve and the preparation of calibration standards 
(in estimating xcs). 
In the next sections, each of these uncertainty sources are 
quantified in detail and combined to obtain an overall measure of 
uncertainty using UKAS guidelines [20], making reference to GUM  
[21] and EURACHEM [22] guidelines. 
4. Quantifying uncertainty sources 
The relative standard uncertainty associated with calibration in 
estimating the amount of THC in case sample xcs is derived by 
combining uncertainty sources from the preparation of calibration 
standards and the calibration curve. 
For simplicity on how each uncertainty component is calculated, 
the uncertainty associated with the preparation of calibration stan-
dards was calculated separately from that of calibration curve. 
4.1. Uncertainty of the calibration standards 
The uncertainty associated with the calibration standards sums 
or combines the uncertainties stated on the Certificates of Analysis 
of the Certified Reference Materials (CRMs) and the inaccuracies of 
all measuring equipment (e.g. pipettes and volumetric flasks) used 
to dilute CRMs and spike blank blood samples when preparing a 
calibration curve. The structure of how the THC CRM was diluted to 
make other solutions in preparing the calibration curve is displayed 
in Fig. 2. 
The volume, tolerance and coverage factor (k) of pipettes and 
volumetric flasks used as given in the manufacturer’s reference 
material, are given in Table 1, along with the number of times each 
pipette and volumetric flask was used in the preparation process for 
each standard solution. 
The standard uncertainty (u) of THC as well as pipettes and vo-
lumetric flasks is given by =u
k
Tolerance and the relative standard 
uncertainty (RSU) is given by =ur uVolume . These are summarised in  
Table 2 together with the uncertainty associated with the prepara-
tion of calibration standards. 
The RSU associated with the preparation of calibration standards 
was obtained by combining the RSU of ur(Cal1−3) and ur(Cal4−10) as: 
Fig. 1. Cause and effect diagram for identifying the sources of uncertainty in quantifying THC in blood. A 25 μ/L pipette is denoted with pip-25 and a 10 mL volumetric flask is 
denoted with flask-10. 
Fig. 2. The structure of THC dilution process for the preparation of the calibration 
curve. 
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4.2. Uncertainty of the calibration curve 
The uncertainty associated with the fitted calibration curve is 























where: Sy∕x is the residual or standard error of regressing y on x. 
b1 is the slope of the regression line. rcs is the number of replicates 
made on the case sample to determine xcs. n is the number of 
measurements used to generate the calibration curve. xcs is the 
mean amount of THC in the case sample. x is the mean value of the 
different calibration standards. xi is the target calibrator con-
centration at the i level. Sxx is the sum of squared deviation of 










cs (6)  
Consider the calibration curve data of peak area ratios for 10 
concentration levels {1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 10} μg/L given in  
Table 3 along with the coefficients of the linear regression and the 
sum of squared deviations. 
The standard error of regression can be computed using Eq. (5) 









From the calibration curve data in Table 3, at each calibration 
level, one replicate is analysed for generating the calibration curve 
according to laboratory protocol. To obtained a more reliable esti-
mate of the standard error, standard errors from previous calibration 
Table 1 
Data on THC CRM purity, pipette and flask used for solutions preparation.         
THC CRM 
THC 
Purity (mg/mL) Tolerance (mg/mL) Coverage factor (k)  
1 0.033 2   
Solutions 
Pipettes/Flask Volume (μ/L) Tolerance (μ/L) Coverage factor(k) Times used 
Stock solution ACAL   
pip-25 25 0.30 2 1 
pip-1000 1000 5 2 2 
Working solution BCAL   
pip-50 50 0.30 2 1 
pip-1000 1000 5 2 7 
Working solution CCAL   
pip-100 100 0.3 2 1 
flask-10 10,000 25 3 1 
Calibration standards 
1–3 μg/L (Cal1−3)   
pip-25 25 0.30 2 9 
pip-50 50 0.30 2 1 
pip-1000 1000 5 2 5 
4–10 μg/L (Cal4−10)   
pip-25 25 0.30 2 7 
pip-50 50 0.30 2 3 
pip-1000 1000 5 2 5    
Table 2 
Calculations of RSU for THC CRM, volumetric flasks, pipettes, stock and working so-
lutions used for calibration standards 1–3 μg/L and 4–10 μg/L.   
RSU of THC CRM, volumetric flasks and pipettes 
= =u (Purity) 0.01650.033
2
, = =u (Purity) 0.0165r
0.0165
1
= =u (pip-25) 0.150.30
2
, = =u (pip-25) 0.006r
0.15
25
= =u (pip-50) 0.150.30
2
, = =u (pip-50) 0.003r
0.15
50
= =u (pip-100) 0.150.30
2
, = =u (pip-100) 0.0015r
0.15
100
= =u (pip-1000) 2.55
2
, = =u (pip-1000) 0.0025r
2.5
1000
= =u (flask-10) 14.4337625
3
, = =u (flask-10) 0.00144r
14.43376
10000
RSU of working standard solution 
= + + ×
= + + ×
=
u u u u(A ) (Purity) (pip-25) 2 (pip-1000)
0.0165 0.006 2 0.0025
0.01791
r r r rCAL
2 2 2
2 2 2
= + + ×
= + + ×
=
u u u u(B ) (A ) (pip-50) 7 (pip-1000)
0.01791 0.003 7 0.0025
0.019327






u u u u(C ) (A ) (pip-100) (flask-10)
0.01791 0.0015 0.00144
0.018
r r r rCAL CAL
2 2 2
2 2 2
RSU of calibration standards 1–3 μg/L and 4–10 μg/L 
= + × + + ×
= + × + + ×
=
u u u u u(Cal ) (B ) 9 (pip-25) (pip-50) 5 (pip-1000)
0.019327 9 0.006 0.003 5 0.0025
0.02716
r r r r r1 3 CAL
2 2 2 2
2 2 2 2
= + × + × + ×
= + × + × + ×
=
u u u u u(Cal ) (C ) 7 (pip-25) 3 (pip-50) 5 (pip-1000)
0.018 7 0.006 3 0.003 5 0.0025
0.0252
r r r r r4 10 CAL
2 2 2 2
2 2 2 2
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4 
curve data can be pooled. Pooling the errors gives a better estimate 
for the standard error of regression by taking into account different 
laboratory conditions over different days. The standard errors of a 
further 10 calibration curve data sets is summarised in Table 4, and the 


















The data for computing the standard errors in Table 4 along with all 
supplementary data files is given in Appendix A. 
Substituting the pooled standard error Sp y x( ) as an estimate for 



























For a given the case sample, two replicates are taken (rcs = 2) and 
the average reported. For an average concentration reading of xcs 
= 2 μg/L, the relative standard uncertainty of the calibration curve 









4.3. Uncertainty of the method precision 
The quality control (QC) data for evaluating the uncertainty of the 
method precision is summarised in Table 5. Blank blood samples 
were spiked with THC at three concentration levels: 2 μg/L (low), 
5 μg/L (medium), and 10 μg/L (high). For each concentration level, 
Table 3 
10 concentration levels versus peak area ratio, linear regression coefficients and the 
sum of squares of regression for the calibration curve data.       
Concentration (x) Peak area 
Ratios (y) 
x x( )2 = +y b b xˆ 0 1 y y( ˆ)2
1 0.50936  10.89000 0.46247 0.00220 
1.5 0.73972  7.84000 0.72863 0.00012 
2 1.00815  5.29000 0.99479 0.00018 
2.5 1.24273  3.24000 1.26095 0.00033 
3 1.53580  1.69000 1.52711 0.00008 
4 2.09479  0.09000 2.05943 0.00125 
5 2.50074  0.49000 2.59175 0.00828 
6 3.06545  2.89000 3.12407 0.00344 
8 4.15375  13.69000 4.18871 0.00122 
10 5.34078  32.49000 5.25336 0.00764 
x =S x x( )xx 2 y y( ˆ)2
4.3  78.6  0.02474   
Intercept b0  −0.06985    
Slope b1  0.53232    
R2  0.9989    
n  10     
Table 4 
The standard error and sum of squares deviation of 11 different calibration curves.      
n n − 1 Sy∕x n S( 1) y x
2
10 9 0.05561 0.02784 
10 9 0.05127 0.02366 
10 9 0.03796 0.01297 
10 9 0.07499 0.05061 
10 9 0.04149 0.01549 
10 9 0.04626 0.01926 
10 9 0.05563 0.02786 
10 9 0.04353 0.01705 
10 9 0.11674 0.12265 
10 9 0.04294 0.01660 
9 8 0.08031 0.05160  
∑(n − 1)  n S( 1) y x
2
98  0.38558    
Table 5 
Quality control data for concentration levels 2 μg/L (Low), 5 μg/L (Medium) and 10 μg/L (High) over 11 different days with three replicates each concentration level.              
Concentration Peak area ratios 
(μg/L) Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Run 7 Run 8 Run 9 Run 10 Run 11  
Low            
2 2.198 1.825 2.144 2.108 2.065 1.810 1.993 1.829 1.786 2.044 1.851  
1.988 1.920 2.166 2.052 2.002 1.806 1.942 1.768 1.880 1.810 1.822  
2.161 1.851 2.182 1.972 2.152 1.795 1.931 1.826 1.785 1.896 1.701 
Mean 2.11567 1.86533 2.16400 2.04400 2.07300 1.80367 1.95533 1.80767 1.81700 1.91667 1.79133 
Std. Dev 0.11210 0.04910 0.01908 0.06835 0.07532 0.00777 0.03308 0.03439 0.05456 0.11836 0.07956             
Medium            
5 4.885 5.067 4.893 4.986 4.884 4.377 4.969 4.475 4.801 4.731 4.405  
4.869 5.266 5.037 4.906 4.913 4.672 4.641 4.549 4.535 4.718 4.472  
4.806 5.086 5.141 4.867 4.863 4.684 4.737 4.388 4.611 4.709 4.402 
Mean 4.85333 5.13967 5.02367 4.91967 4.88667 4.57767 4.78233 4.47067 4.64900 4.71933 4.42633 
Std. Dev 0.04177 0.10982 0.12454 0.06067 0.02511 0.17389 0.16863 0.08059 0.13701 0.01106 0.03958             
High            
10 9.952 9.945 9.851 10.306 10.054 9.219 9.493 9.732 9.327  8.609  
9.910 10.235 9.940 10.299 9.616 9.249 9.091 9.322 8.988 10.972   
10.002 9.941 9.740 10.840 10.473 9.275 9.225 9.224 9.255 11.199 8.936 
Mean 9.95467 10.04033 9.84367 10.48167 10.04767 9.24767 9.26967 9.42600 9.19000 11.08550 8.77250 
Std. Dev 0.04606 0.16860 0.10020 0.31035 0.42854 0.02802 0.20469 0.26950 0.17860 0.16051 0.23122    
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three replicates were analysed over eleven separate days using a 
freshly prepared calibration line each day. 
The uncertainty associated with the method precision u 
(Precision) is estimated for each concentration level 2 μg/L (Low), 
5 μg/L (Medium) and 10 μg/L (High) using a pooled standard devia-















νi is the degrees of freedom of the ith sample, Si is standard deviation 
of the ith sample and rcs is the number of case sample replicates. As 
noted by Kadis [7], rcs is used in the denominator of Eq. (10) to avoid 
underestimation of the uncertainty associated with the method 
precision. 
The relative standard uncertainty of the method precision is 
calculated by dividing the standard uncertainty by its nominal value 






The calculations for the uncertainty of method precision are de-
tailed in Table 6 for each concentration level. For a given mean reading 
from a case sample, the relative standard uncertainty value (Table 6) 
for which the nominal value (NV) was closest to the mean reading xcs 
was used. Hence, for xcs = 2, the closet nominal value is (NV = 2) and 
the relative standard uncertainty of the method precision is: 
=u (Precision) 0.02415r
4.4. Uncertainty of the sample volume 
The RSU of the volume u(V) of case blood sample is equivalent to the 
uncertainty of the pipette used which is the pipette pip-1000. Where 
multiple equipment is used in the sample preparation, the uncertainty 
from each equipment can be combined as shown in Tables 1 and 2. From  
Tables 1 and 2, the pipette pip-1000 has volume 1000 μ/L with a toler-
ance of 5 μ/L and a reference certificate coverage factor of 2. 
= = µu V( ) 5
2
2.5 L






5. Combined and expanded uncertainty 
5.1. Calculating the combined uncertainty 
The concentration of THC in case sample from Eq. (2) is 
= × = µx 1 2THC 21 g/L. 
Table 6 
Uncertainty of the method precision calculation for concentration levels 2 μg/L (low), 5 μg/L (medium), and 10 μg/L (high).           
Concentration Nominalvalue 
(NV) 
Standard.deviation Degrees of 
Freedom  






μg/L S ν q = S2 × ν rcs =u S rp cs ur = u∕NV  
Low 2 0.11210 2 0.02513 0.06832 2 0.04831 0.02415   
0.04910 2 0.00482       
0.01908 2 0.00073       
0.06835 2 0.00934       
0.07532 2 0.01135       
0.00777 2 0.00012       
0.03308 2 0.00219       
0.03439 2 0.00236       
0.05456 2 0.00595       
0.11836 2 0.02802       
0.07956 2 0.01266        
∑ν = 22 ∑q = 0.10268     
Medium 5 0.04177 2 0.00349 0.10412 2 0.07362 0.01472   
0.10982 2 0.02412       
0.12454 2 0.03102       
0.06067 2 0.00736       
0.02511 2 0.00126       
0.17389 2 0.06047       
0.16863 2 0.05687       
0.08059 2 0.01299       
0.13701 2 0.03754       
0.01106 2 0.00024       
0.03958 2 0.00313        
∑ν = 22 ∑q = 0.23851     
High 10 0.04606 2 0.00424 0.22525 2 0.15927 0.01593   
0.16860 2 0.05685       
0.10020 2 0.02008       
0.31035 2 0.19263       
0.42854 2 0.36728       
0.02802 2 0.00157       
0.20469 2 0.08379       
0.26950 2 0.14526       
0.17860 2 0.06380       
0.16051 1 0.02576       
0.23122 1 0.05346        
∑ν = 20 ∑q = 1.01474     
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The combined uncertainty uc is obtained by combing all the in-
dividual uncertainty components as follows: 
= + + +u
x
u u u u V(Precision) (CalStd) (CCur) ( )c r r r r
THC
Hence, 
= × + + +
= × + + +
= µ
u x u u u u V(Precision) (CalStd) (CCur) ( )
2 0.02415 0.0371 0.04813 0.0025
0.131 g L
c r r r rTHC
2 2 2 2
5.2. The effective degrees of freedom and coverage factor 
The obtain a suitable coverage factor k, the effective degrees of 
freedom νeff is calculated using the Welch-Satterthwaite equation 











where uc is the combined uncertainty, u(l) is the individual standard 
uncertainty component l, combined to obtain uc, and νl is the degrees 
of freedom for each uncertainty component l. With the use of re-
lative standard uncertainties for the combined uncertainty [21], 











































The degrees of freedom for the preparation of calibration standards 
and sample volume are unknown and therefore ν(CalStd) = ν(V) = ∞ . 
From the t-distribution table with a 99.7% confidence level [26], a 
coverage factor of =k 3,99.7%eff is chosen for calculating the expanded 
uncertainty. 
5.3. Calculating the expanded uncertainty 
Finally, the expanded uncertainty is obtained by multiplying the 








The concentration of THC in the case sample is given by 















Understanding uncertainty sources and appropriately quanti-
fying them can have a potentially significant impact on decision 
making processes. In the judicial system for example, where THC 
concentrations in a blood sample can be compared to a legal limit, 
taking into account a calculated measurement uncertainty asso-
ciated with an analytical method, MU plays a crucial roll in the de-
cision making process, serving as a measure of confidence in a 
reported analytical result. 
Using the bottom-up approach with laboratory validation data, the 
MU for quantifying THC in blood using LC/MS/MS analysis was de-
termined. The combined uncertainty was estimated to be 0.131 μg/L 
at a concentration of 2 μg/L (<7%). Expanding the combined un-
certainty at a 99.7% confidence level gave an expanded uncertainty of 
0.393 μg/L. 
These calculations not only enable the laboratory to quantify the 
uncertainty associated with a quantitative result, but can also be 
used to identify the sources of uncertainty with potential influence 
and determine if the method can be improved to reduce the un-
certainty. 
It can be seen from the calculation of the combined uncertainty 
and Fig. 3 that the largest contribution to the overall method un-
certainty for this particular analytical method is from the calibration 
curve with sample volume contributing the least. 
The linear regression of the curve is performed by instrument 
software, which was optimised during method development and 
therefore cannot be changed and/or improved. A potential reason for 
the uncertainty of the calibration curve contributing the most is the 
problem of double counting, as the uncertainty components are not 
entirely independent and overlap [7]. Additionally, given that a fresh 
calibration is prepared on a daily basis according to protocol, the 
variation in calibrations is partly accounted for in the precision 
estimate [7]. 
The risk of double counting is also true for the uncertainty of the 
method precision and the method recovery (extraction efficiency), 
which in most cases, it is difficult to separate or avoid [7]. Some 
authors have minimised the risk of double counting by including the 
uncertainty of the method recovery and leaving out the uncertainty 
of the method precision [23,24,5,25,7], with further suggestions on 
minimising this risk given in [7]. 
Fig. 3. The contribution of individual uncertainty sources to the total uncertainty.  
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It is worth mentioning two important uncertainty components 
not calculated for; the uncertainty associated with sample effect and 
the uncertainty of method recovery. The uncertainty of sample effect 
which evaluates the effect of different sample matrices was not 
evaluated due to legal restrictions on the use of case blood samples 
during validation experiments. According to the guideline [Forensic 
Service Providers (FSPs) guide for the Analysis of Drugs in support of 
Section 5a of the Road Traffic Act 1988 (as amended)], an evaluation 
of analyte recovery was not required if the method was “sufficient to 
allow detection and quantification at the lowest end of the validated 
range”. Additionally, given the use of deuterated internal standard 
(THC-d3) matched to the drug which has similar recovery as the drug 
of interest (THC), any THC ‘lost’ during the extraction process is 
expected to be offset by the loss in THC-d3. It is, however, ac-
knowledge that recovery is unlikely to be 100% given the analytical 
procedure and could be accounted for with its associated un-
certainty included in the overall uncertainty. 
It should be noted that the determination of the method uncertainty 
outlined above does not take into consideration the bias (accuracy/ 
trueness) of the method. Whilst the bias of a method should be eval-
uated (and was in this case −2.938% at 2 μg/L), corrections for bias can 
be made independently of MU. This is the case for the laboratory 
casework, in accordance with standard practitioner guidelines [Forensic 
Science Regulator Codes of Practice and Conduct - FSR -C-133]. 
In minimising the overall uncertainty, one factor that can pos-
sibly be improved is the preparation of the standards and spiking of 
the calibration curve. Minimising the number of times each pipette 
is used, or using volumetric flasks instead of pipettes would reduce 
this uncertainty component. Also, in estimating the uncertainty as-
sociated with pipettes and volumetric flasks, additional uncertainty 
that could possibly influence instrument performance is tempera-
ture effect and repeatability. Laboratory temperature was varied 
during the validation and has therefore been accounted for in the 
precision experiments. 
The experimental design of the validation (3 replicates at 3 con-
centration levels over 11 days) is one of the more comprehensive de-
signs, nevertheless it is possible that extending the validation to more 
replicates over more days may provide more accurate or improved 
precision data. The current design is however, more than adequate for 
method validation within the forensic toxicological community 
[Forensic Science Regulator Codes of Practice and Conduct-FSR-C-133]. 
Using the methodology underpinning these calculations for de-
riving the overall uncertainty, work is on going to create an appli-
cation as part of a statistical tool box project that implements these 
calculations. The statistical tool box will be releasing all applications 
open source and more information can be found in Appendix B. 
7. Conclusion 
In summary, a detailed systematic approach has been provided 
for identifying the sources of measurement uncertainty within a 
method validated for the purpose of quantifying THC in blood 
samples and estimating their individual contribution to the overall 
uncertainty of the analytical method. The data associated with each 
calculation is given and detailed step-by-step calculations are pro-
vided to illustrate a possible way of estimating MU using laboratory 
validation data. 
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